Truist Securities Downgrades Corcept Therapeutics (CORT) to Hold
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $22.66 --0%
Rating Summary:
7 Buy, 8 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 16
Rating Summary:
7 Buy, 8 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 16
Join SI Premium – FREE
Truist Securities analyst Gregory Fraser downgraded Corcept Therapeutics (NASDAQ: CORT) from Buy to Hold with a price target of $30.00.
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $28.66 yesterday.
You May Also Be Interested In
- HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
- Stifel Canada Downgrades Saipem (SPM:IM) (SAPMF) to Hold
- HSBC Downgrades AngloGold Ashanti (AU) to Reduce
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
